Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
US9771408B2 · kind B2 · utility
4Cited by
4References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 14, 2015 |
| Grant date | Sep 26, 2017 |
| Priority date | — |
| Expiry date | Nov 23, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/47
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates in general to therapeutic fusion proteins useful to treat lysosomal storage diseases and methods for treating such diseases. Exemplary therapeutic fusion proteins comprise a lysosomal enzyme, a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. Also provided are compositions and methods for treating Mucopolysaccharidosis Type IIIB (Sanfilippo B Syndrome), comprising a targeted therapeutic fusion protein comprising alpha-N-acetylglucosaminidase (Naglu), a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.